Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1128815

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all patients who would benefit from medical cannabis are able to access that treatment on prescription on the NHS.
	tabling member constituency	Birkenhead
	tabling member printed	Frank Field
	uin	259011
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>Cannabis-based products for medicinal use are no different from other medicines, and existing systems for the funding of both licensed and unlicensed medicines apply.</p><p>Any medicines which receive a marketing authorisation from the Medicines and Healthcare Products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by the National Institute for Health and Care Excellence. This is the foundation of National Health Service decisions about routine funding, and applies to all licensed medicines. For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS Trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p>My Rt. hon. Friend the Secretary of State for Health and Social Care has heard patients report difficulties in accessing medicinal cannabis. As a result, he asked the Department to work closely with NHS England to undertake a rapid process evaluation. This is underway and will review NHS system processes to identify and make recommendations to address any barriers to clinically appropriate prescribing, should they exist.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:52:22 answering member 4455 label Biography information for Seema Kennedy
	tabling member	478 label Biography information for Lord Field of Birkenhead

1129369

	registered interest
	date	03/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with (a) NHS England, (b) manufacturers and (c) NICE on funding arrangements for accessing (a) licensed and (b) unlicensed cannabis-based medicines on the NHS.
	tabling member constituency	Dudley North
	tabling member printed	Ian Austin
	uin	259109
	answer	answer is ministerial correction date of answer 11/06/2019 answer text <p>In developing policy on the rescheduling of cannabis-based products for medicinal use, the Government has applied existing arrangements for accessing licensed and unlicensed medicines on the National Health Service. The Department has not had discussions with NHS England, manufacturers or the National Institute for Health and Care Excellence (NICE) on funding arrangements for accessing licensed or unlicensed cannabis-based products, beyond the existing arrangements.</p><p>The recent changes to the law to reschedule cannabis-based products for medicinal use, does not impact on the availability of existing licensed cannabis-based medicinal products, such as Sativex and Nabilone. Any medicines which receive a marketing authorisation from the Medicines and Healthcare products Regulatory Agency or European Medicines Agency will be assessed for cost effectiveness by NICE. This is the foundation of NHS decisions about routine funding, and applies to all licensed medicines.</p><p>For unlicensed medicines, the normal NHS medicines governance systems apply, as they do to all locally funded unlicensed treatments. These processes support good clinical practice and safe and effective prescribing. Decisions will be taken, at NHS trust level on a case by case basis, based on the needs of the individual patient and the evidence of efficacy and cost effectiveness available.</p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/06/2019 16:54:00 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1511 label Biography information for Lord Austin of Dudley